Please assess the completion status of the following clinical trial:

Trial Title: Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Untreated stage A CLL patients~* Healthy volunteers~Exclusion Criteria:~* Patients with other malignancies~* Patients receiving corticosteroids or other immunosuppressive drugs~* Patients who have received vaccination against influenza in the past 6 months~* Patients who have had an allergic reaction to a flu shot in the past, or have an allergy to eggs or who previously developed Guillain-Barré syndrome within 6 weeks of getting a flu shot~* Patients failing to give informed consent.~* Patients using homeopathic remedies such as echniaea cream.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A CLL patients (Type: ACTIVE_COMPARATOR): Vaccination with current trispecific influenza vaccine Day 1
- Group B CLL patients (Type: EXPERIMENTAL): Vaccination with current trispecific influenza vaccine Day 1, together with the application of Imiquimod cream to the vaccination site on day 2 to 6.
- Group C volunteers (Type: ACTIVE_COMPARATOR): Vaccination with current trispecific influenza vaccine Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).